Table 8.
Average score of SF-12v2 components reported by COVID-19 survivors and healthy participants.
| SF-12v2 component | COVID-19 patients (n = 90) mean (SD) | Healthy participants (n = 18) mean (SD) | Mean difference between groups (95% CI) | P-value | Effect size |
|---|---|---|---|---|---|
| PF | 73.89 (26.21) | 93.06 (11.52) | −19.17 (−31.69 to −6.65) | 0.003 | −0.95 |
| RP | 58.06 (27.94) | 67.36 (27.50) | −9.30 (−23.57 to 4.96) | 0.199 | |
| BP | 55.83 (29.04) | 69.44 (26.51) | −13.61 (−28.28 to 1.05) | 0.069 | |
| GH | 45.28 (27.00) | 55.56 (29.15) | −10.28 (−24.28 to 3.72) | 0.149 | |
| VT | 58.89 (26.05) | 73.61 (13.48) | −14.72 (−27.25 to −2.20) | 0.022 | −0.71 |
| SF | 36.94 (32.72) | 75.00 (29.70) | −38.06 (−54.57 to −21.54) | <0.001 | −1.22 |
| RE | 62.92 (24.96) | 72.92 (24.72) | −10.00 (−22.76 to 2.76) | 0.123 | |
| MH | 65.28 (21.02) | 76.39 (15.39) | −11.11 (−21.46 to −0.76) | 0.036 | −0.60 |
| PCS | 37.85 (12.63) | 46.56 (9.63) | −8.71 (−14.96 to −2.47) | 0.007 | −0.78 |
| MCS | 38.81 (13.54) | 46.56 (11.90) | −7.75 (−14.55 to −0.94) | 0.026 | −0.61 |